Ascensia Diabetes Care Launches Patient Assistance Program to Provide Wider Access to Eversense Continuous Blood Glucose Monitoring System


PARSIPPANY, NJ, July 20, 2021 / PRNewswire / – Ascensia Diabetes Care, a global diabetes company, announced it has introduced a patient assistance program in United States to reduce the reimbursable costs associated with Eversense® Continuous Glucose Monitoring System (CGM).

Ascensia Diabetes Care Logo

As part of the program, which is available immediately, eligible patients starting or continuing with the Eversense CGM system will be required to pay the first $ 100 of their reimbursable expenses. Ascensia will then cover up to $ 300 of the remaining balance for each 90-day sensor. Any additional costs will be the responsibility of the user of the system. Overall, the program has the potential to save eligible Eversense users up to $ 1,200 per year on their sensor costs accumulated over 90 days.

To learn more about the program, potential and current Eversense users can go to and complete the eligibility form, after which the Ascensia team will contact you on the next steps. They can also chat with their health care provider.

Marie Puncochar, Head of the Ascensia region in the United States, said: “People living with diabetes and their caregivers tell us how transformative the Eversense system can be in making it easier to manage their diabetes. System users appreciate the discretion of Eversense with a removable transmitter, peace of mind with body alerts, and the freedom offered by a 90-day sensor.

“Our fundamental goal at Ascensia is to simplify and improve the lives of people with diabetes through technologies that facilitate better outcomes and reduce the burden of disease management. So we want to be able to offer Eversense to as many people as possible and believe that more than half of people using insulin in the United States could be eligible for our patient assistance program. Our goal is to make Eversense more affordable and to provide better access to this unique and innovative diabetes management technology.

The Eversense CGM system consists of a fluorescence-based sensor, a smart transmitter worn on the sensor, and a mobile app to display glucose readings, trends and alerts. In addition to showcasing the first long-term implantable CGM sensor, the system is also the first to feature a smart transmitter that provides wearers with discrete body-to-body vibration alerts for high and low glucose. It can also be removed, recharged and reattached to the skin without throwing the sensor away. The sensor is inserted subcutaneously into the upper arm by a healthcare provider via a brief in-office procedure.

  1. Christiansen, MP et al. (2009). A prospective multicenter evaluation of the precision and safety of an implanted continuous glucose sensor: the PRECISION study. Diabetes Technology & Therapeutic, 21 (5), 231-237.doi: 10.1089 / dia.2019.0020.

  2. Slattery D, Choudhary P. Clinical Use of Continuous Blood Glucose Monitoring in Adults with Type 1 Diabetes. Diabetes Technology and Therapeutics 2017; 19 (2): 55-61. DOI: 10.1089.dia.2017.0051.

Logo –



View original content: – system-301337187.html

SOURCE Ascensia Diabetes Care


About Author

Comments are closed.